Impairment of Vα24-Jα18+Vβ11+ natural killer T cells in adult acute lymphoblastic leukemia patients
Type I natural killer T (NKT) cells are attractive candidates for cancer immunotherapy. In this study, we examined the characteristics of type I NKT cells in patients with adult B-cell acute lymphoblastic leukemia (ALL). We first identified type I NKT cells as Vα24-Jα18 and Vβ11 double-positive CD3+...
Saved in:
Published in | Experimental cell research Vol. 374; no. 1; pp. 69 - 75 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.01.2019
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Type I natural killer T (NKT) cells are attractive candidates for cancer immunotherapy. In this study, we examined the characteristics of type I NKT cells in patients with adult B-cell acute lymphoblastic leukemia (ALL). We first identified type I NKT cells as Vα24-Jα18 and Vβ11 double-positive CD3+ lymphocytes. Using this method, we found that the adult B-cell ALL patients presented significantly lower level of type I NKT cells than the age- and sex-matching control subjects. The expression of IL-21 by type I NKT cells was then examined using intracellular flow cytometry, which showed that with α-GalCer stimulation, the adult B-cell ALL patients presented significantly lower level of IL-21+ type I NKT cells than control subjects. By both flow cytometry and ELISA, we found that the vast majority of IL-21-expressing type I NKT cells expressed IL-21R, which was also reduced in adult B-cell ALL patients. Using an in vitro co-culture system, we demonstrated that IL-21R+, but not IL-21R-, type I NKT cells could promote the IFN-γ, granzyme B, and perforin expression by CD8 T cells in an IL-21-dependent fashion. This type I NKT cell-mediated stimulatory effect was reduced in adult B-cell ALL patients than in control subjects. In addition, we observed a positive correlation between the frequency of IL-21R+ type I NKT cells and the frequencies of IFN-γ-, granzyme B-, and perforin-expressing circulating CD8 T cells in adult B-cell ALL patients directly ex vivo. Overall, this study identified an IL-21-related impairment in type I NKT cells from adult B-cell ALL patients.
•Type I NKT cell frequency was significantly reduced in adult B-cell ALL patients.•Type I NKT cells from adult B-cell ALL patients showed lower IL-21 and IL-21R levels.•IL-21R+ NKT cells in ALL showed reduced capacity to promote CD8 T cell responses.•IL-21R+ type I NKT cell-mediated effects required IL-21 release.•IL-21R+ NKT cell was correlated with effector CD8 T cell frequency in ALL patients. |
---|---|
AbstractList | Type I natural killer T (NKT) cells are attractive candidates for cancer immunotherapy. In this study, we examined the characteristics of type I NKT cells in patients with adult B-cell acute lymphoblastic leukemia (ALL). We first identified type I NKT cells as Vα24-Jα18 and Vβ11 double-positive CD3
lymphocytes. Using this method, we found that the adult B-cell ALL patients presented significantly lower level of type I NKT cells than the age- and sex-matching control subjects. The expression of IL-21 by type I NKT cells was then examined using intracellular flow cytometry, which showed that with α-GalCer stimulation, the adult B-cell ALL patients presented significantly lower level of IL-21
type I NKT cells than control subjects. By both flow cytometry and ELISA, we found that the vast majority of IL-21-expressing type I NKT cells expressed IL-21R, which was also reduced in adult B-cell ALL patients. Using an in vitro co-culture system, we demonstrated that IL-21R
, but not IL-21R
, type I NKT cells could promote the IFN-γ, granzyme B, and perforin expression by CD8 T cells in an IL-21-dependent fashion. This type I NKT cell-mediated stimulatory effect was reduced in adult B-cell ALL patients than in control subjects. In addition, we observed a positive correlation between the frequency of IL-21R
type I NKT cells and the frequencies of IFN-γ-, granzyme B-, and perforin-expressing circulating CD8 T cells in adult B-cell ALL patients directly ex vivo. Overall, this study identified an IL-21-related impairment in type I NKT cells from adult B-cell ALL patients. Type I natural killer T (NKT) cells are attractive candidates for cancer immunotherapy. In this study, we examined the characteristics of type I NKT cells in patients with adult B-cell acute lymphoblastic leukemia (ALL). We first identified type I NKT cells as Vα24-Jα18 and Vβ11 double-positive CD3+ lymphocytes. Using this method, we found that the adult B-cell ALL patients presented significantly lower level of type I NKT cells than the age- and sex-matching control subjects. The expression of IL-21 by type I NKT cells was then examined using intracellular flow cytometry, which showed that with α-GalCer stimulation, the adult B-cell ALL patients presented significantly lower level of IL-21+ type I NKT cells than control subjects. By both flow cytometry and ELISA, we found that the vast majority of IL-21-expressing type I NKT cells expressed IL-21R, which was also reduced in adult B-cell ALL patients. Using an in vitro co-culture system, we demonstrated that IL-21R+, but not IL-21R-, type I NKT cells could promote the IFN-γ, granzyme B, and perforin expression by CD8 T cells in an IL-21-dependent fashion. This type I NKT cell-mediated stimulatory effect was reduced in adult B-cell ALL patients than in control subjects. In addition, we observed a positive correlation between the frequency of IL-21R+ type I NKT cells and the frequencies of IFN-γ-, granzyme B-, and perforin-expressing circulating CD8 T cells in adult B-cell ALL patients directly ex vivo. Overall, this study identified an IL-21-related impairment in type I NKT cells from adult B-cell ALL patients. •Type I NKT cell frequency was significantly reduced in adult B-cell ALL patients.•Type I NKT cells from adult B-cell ALL patients showed lower IL-21 and IL-21R levels.•IL-21R+ NKT cells in ALL showed reduced capacity to promote CD8 T cell responses.•IL-21R+ type I NKT cell-mediated effects required IL-21 release.•IL-21R+ NKT cell was correlated with effector CD8 T cell frequency in ALL patients. Type I natural killer T (NKT) cells are attractive candidates for cancer immunotherapy. In this study, we examined the characteristics of type I NKT cells in patients with adult B-cell acute lymphoblastic leukemia (ALL). We first identified type I NKT cells as Vα24-Jα18 and Vβ11 double-positive CD3+ lymphocytes. Using this method, we found that the adult B-cell ALL patients presented significantly lower level of type I NKT cells than the age- and sex-matching control subjects. The expression of IL-21 by type I NKT cells was then examined using intracellular flow cytometry, which showed that with α-GalCer stimulation, the adult B-cell ALL patients presented significantly lower level of IL-21+ type I NKT cells than control subjects. By both flow cytometry and ELISA, we found that the vast majority of IL-21-expressing type I NKT cells expressed IL-21R, which was also reduced in adult B-cell ALL patients. Using an in vitro co-culture system, we demonstrated that IL-21R+, but not IL-21R-, type I NKT cells could promote the IFN-γ, granzyme B, and perforin expression by CD8 T cells in an IL-21-dependent fashion. This type I NKT cell-mediated stimulatory effect was reduced in adult B-cell ALL patients than in control subjects. In addition, we observed a positive correlation between the frequency of IL-21R+ type I NKT cells and the frequencies of IFN-γ-, granzyme B-, and perforin-expressing circulating CD8 T cells in adult B-cell ALL patients directly ex vivo. Overall, this study identified an IL-21-related impairment in type I NKT cells from adult B-cell ALL patients.Type I natural killer T (NKT) cells are attractive candidates for cancer immunotherapy. In this study, we examined the characteristics of type I NKT cells in patients with adult B-cell acute lymphoblastic leukemia (ALL). We first identified type I NKT cells as Vα24-Jα18 and Vβ11 double-positive CD3+ lymphocytes. Using this method, we found that the adult B-cell ALL patients presented significantly lower level of type I NKT cells than the age- and sex-matching control subjects. The expression of IL-21 by type I NKT cells was then examined using intracellular flow cytometry, which showed that with α-GalCer stimulation, the adult B-cell ALL patients presented significantly lower level of IL-21+ type I NKT cells than control subjects. By both flow cytometry and ELISA, we found that the vast majority of IL-21-expressing type I NKT cells expressed IL-21R, which was also reduced in adult B-cell ALL patients. Using an in vitro co-culture system, we demonstrated that IL-21R+, but not IL-21R-, type I NKT cells could promote the IFN-γ, granzyme B, and perforin expression by CD8 T cells in an IL-21-dependent fashion. This type I NKT cell-mediated stimulatory effect was reduced in adult B-cell ALL patients than in control subjects. In addition, we observed a positive correlation between the frequency of IL-21R+ type I NKT cells and the frequencies of IFN-γ-, granzyme B-, and perforin-expressing circulating CD8 T cells in adult B-cell ALL patients directly ex vivo. Overall, this study identified an IL-21-related impairment in type I NKT cells from adult B-cell ALL patients. |
Author | Xie, Shiting Zeng, Hanyan Deng, Manman Yu, Lian Luo, Yiming Xu, Bing Zhao, Jintao Zhou, Yong Zhao, Haijun Li, Zhifeng |
Author_xml | – sequence: 1 givenname: Haijun surname: Zhao fullname: Zhao, Haijun organization: Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Medical College of Xiamen University, Xiamen 361003, PR China – sequence: 2 givenname: Zhifeng surname: Li fullname: Li, Zhifeng organization: Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Medical College of Xiamen University, Xiamen 361003, PR China – sequence: 3 givenname: Shiting surname: Xie fullname: Xie, Shiting organization: Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Medical College of Xiamen University, Xiamen 361003, PR China – sequence: 4 givenname: Yiming surname: Luo fullname: Luo, Yiming organization: Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Medical College of Xiamen University, Xiamen 361003, PR China – sequence: 5 givenname: Yong surname: Zhou fullname: Zhou, Yong organization: Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Medical College of Xiamen University, Xiamen 361003, PR China – sequence: 6 givenname: Manman surname: Deng fullname: Deng, Manman organization: Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Medical College of Xiamen University, Xiamen 361003, PR China – sequence: 7 givenname: Hanyan surname: Zeng fullname: Zeng, Hanyan organization: Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Medical College of Xiamen University, Xiamen 361003, PR China – sequence: 8 givenname: Jintao surname: Zhao fullname: Zhao, Jintao organization: Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Medical College of Xiamen University, Xiamen 361003, PR China – sequence: 9 givenname: Lian surname: Yu fullname: Yu, Lian email: yulian_an_ly@126.com organization: Department of Hematology and Rheumatology, Longyan First Hospital, Affiliated to Fujian Medical University, Longyan 364000, PR, China – sequence: 10 givenname: Bing surname: Xu fullname: Xu, Bing email: bingxudr@sina.com organization: Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Medical College of Xiamen University, Xiamen 361003, PR China |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30439366$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kb1uFDEUhS0URDaBJ0BCLpGiGXxt7-xMQYEifoIi0YS0lse-Ft54frA9iH2s8CD7THjZpKFI5eb7jq7POSMn4zQiIa-B1cCgebetd_jbxJozaGuAmrH2GVkB61jFJecnZMUYyEq2fHNKzlLaskK00Lwgp4JJ0YmmWRF3NczaxwHHTCdHb_f3XFZf9_fQXtzu_wBc0FHnJepA73wIGOkNNRhCon6k2i4hU22WjDTshvnH1Aedsjc04HKHg9d01tmX6PSSPHc6JHz18J6T758-3lx-qa6_fb66_HBdGb6RuULJ7do4J6QEZ9fYNdrqDTMbg2vpWita2UvXgDWcOd11lvfY9L3oWcd5a1Gck7fH3DlOPxdMWQ0-HQ7WI05LUhzEGkq6bAr65gFd-gGtmqMfdNypx24K0B0BE6eUIjplfC7_mcYctQ8KmDrsoLbq3w7qsIMCUKXl4or_3Mf4p633RwtLRb88RpVMqc-g9RFNVnbyT_p_AduMpTA |
CitedBy_id | crossref_primary_10_1016_j_clim_2019_05_011 |
Cites_doi | 10.1182/blood-2008-06-161281 10.1038/ni.1942 10.1038/82771 10.4049/jimmunol.1001018 10.1073/pnas.0801631105 10.1200/JCO.2014.59.1636 10.1172/JCI37869 10.4049/jimmunol.167.6.3114 10.3389/fimmu.2013.00438 10.1371/journal.pone.0020702 10.1038/cti.2013.7 10.1155/2012/720803 10.1016/j.it.2016.06.001 10.1128/JVI.01053-10 10.1038/nri3328 10.4049/jimmunol.178.5.2827 10.1155/2015/652875 10.1038/cti.2016.14 10.1084/jem.20022227 10.1056/NEJMoa1605085 10.3389/fimmu.2017.01178 10.1111/j.1476-5381.2012.02108.x 10.1002/eji.201242531 10.1038/nri3369 10.1016/j.clim.2010.10.005 10.4049/jimmunol.1800429 10.1073/pnas.95.10.5690 10.1002/cncr.20668 |
ContentType | Journal Article |
Copyright | 2018 Elsevier Inc. Copyright © 2018 Elsevier Inc. All rights reserved. |
Copyright_xml | – notice: 2018 Elsevier Inc. – notice: Copyright © 2018 Elsevier Inc. All rights reserved. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1016/j.yexcr.2018.11.008 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1090-2422 |
EndPage | 75 |
ExternalDocumentID | 30439366 10_1016_j_yexcr_2018_11_008 S0014482718308553 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- --K --M -DZ -~X .~1 0R~ 1B1 1RT 1~. 1~5 4.4 457 4G. 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAXUO ABFNM ABFRF ABGSF ABJNI ABMAC ABOCM ABPPZ ABUDA ABYKQ ACDAQ ACGFO ACGFS ACNCT ACPRK ACRLP ADBBV ADEZE ADUVX AEBSH AEFWE AEHWI AEKER AENEX AFKWA AFTJW AFXIZ AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJOXV ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ AXJTR BKOJK BLXMC C45 CS3 DM4 DOVZS DU5 EBS EFBJH EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA IHE J1W K-O KOM L7B LG5 LX2 M41 MO0 N9A O-L O9- OAUVE OVD OZT P-8 P-9 P2P PC. PQQKQ Q38 RIG RNS ROL RPZ SCC SDF SDG SDP SES SPCBC SSU SSZ T5K TEORI TWZ VQA WH7 Y6R YZZ ZA5 ZCA ZMT ZU3 ~G- ~KM .55 .GJ 29G 3O- 53G 9M8 AAQXK AATTM AAXKI AAYWO AAYXX ABDPE ABEFU ABWVN ABXDB ACKIV ACRPL ACVFH ADCNI ADFGL ADMUD ADNMO ADVLN ADXHL AEIPS AETEA AEUPX AFJKZ AFPUW AGCQF AGHFR AGQPQ AGRDE AGRNS AI. AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP ASPBG AVWKF AZFZN BNPGV CAG CITATION COF FA8 FEDTE FGOYB G-2 HLW HVGLF HZ~ LPU MVM NEJ OHT R2- SBG SEW SSH VH1 WUQ X7L X7M XOL XPP YYP ZGI ZKB CGR CUY CVF ECM EIF NPM 7X8 EFKBS |
ID | FETCH-LOGICAL-c274t-e42d5cff3441fd5e96ada70c7ce54f8d384b4f61dc20fa99d2be6bb3b09228de3 |
IEDL.DBID | .~1 |
ISSN | 0014-4827 1090-2422 |
IngestDate | Thu Aug 07 15:06:32 EDT 2025 Wed Feb 19 02:30:11 EST 2025 Thu Apr 24 23:08:31 EDT 2025 Tue Jul 01 00:59:37 EDT 2025 Fri Feb 23 02:12:53 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Acute lymphoblastic leukemia Natural killer T cells IL-21 |
Language | English |
License | Copyright © 2018 Elsevier Inc. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c274t-e42d5cff3441fd5e96ada70c7ce54f8d384b4f61dc20fa99d2be6bb3b09228de3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 30439366 |
PQID | 2135134446 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_2135134446 pubmed_primary_30439366 crossref_citationtrail_10_1016_j_yexcr_2018_11_008 crossref_primary_10_1016_j_yexcr_2018_11_008 elsevier_sciencedirect_doi_10_1016_j_yexcr_2018_11_008 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2019-01-01 2019-01-00 20190101 |
PublicationDateYYYYMMDD | 2019-01-01 |
PublicationDate_xml | – month: 01 year: 2019 text: 2019-01-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Experimental cell research |
PublicationTitleAlternate | Exp Cell Res |
PublicationYear | 2019 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
References | Terabe, Matsui, Park, Mamura, Noben-Trauth, Donaldson (bib11) 2003 Jabbour, Pui, Kantarjian (bib1) 2018 Terabe, Matsui, Noben-Trauth, Chen, Watson, Donaldson (bib10) 2000 Nair, Dhodapkar (bib7) 2017 Coquet, Chakravarti, Kyparissoudis, McNab, Pitt, McKenzie (bib12) 2008 Kawano, Cui, Koezuka, Toura, Kaneko, Sato (bib21) 1998 Coquet, Kyparissoudis, Pellicci, Besra, Berzins, Smyth (bib23) 2007 Nakagawa, Serizawa, Motoki, Sato, Ueno, Iijima (bib19) 2000 Fallarini, Paoletti, Orsi Battaglini, Lombardi (bib29) 2012 Wingender, Krebs, Beutler, Kronenberg (bib24) 2010 Song, Asgharzadeh, Salo, Engell, Wu, Sposto (bib31) 2009 Rossjohn, Pellicci, Patel, Gapin, Godfrey (bib6) 2012 Pilones, Aryankalayil, Demaria (bib8) 2012 Gowda, Roda, Hussain, Ramanunni, Joshi, Schmidt (bib18) 2008; 111 Miura, Kawana, Schust, Fujii, Yokoyama, Iwasawa (bib30) 2010 Kantarjian, Thomas, O’Brien, Cortes, Giles, Jeha (bib3) 2004 Carreño, Saavedra-Ávila, Porcelli (bib33) 2016 Spanoudakis, Hu, Naresh, Terpos, Melo, Reid (bib27) 2009 Coquet, Skak, Davis, Smyth, Godfrey (bib15) 2013; 2 Bai, Picard, Anderson, Chaudhary, Luoma, Jabri (bib13) 2012 Hix, Shi, Brutkiewicz, Stein, Wang, Zhang (bib28) 2011 Bhatt, Matthews, Parvin, Sarosiek, Zhao, Jiang (bib17) 2015; 126 De Santo, Arscott, Booth, Karydis, Jones, Asher (bib32) 2010 Kawano, Nakayama, Kamada, Kaneko, Harada, Ogura (bib22) 1999 Dudek, Martin, Garg, Agostinis (bib20) 2013 Brennan, Brigl, Brenner (bib5) 2013 Altman, Benavides, Das, Bassiri (bib9) 2015 Ngai, Tian, Courtney, Ravari, Guo, Liu (bib16) 2018 Pui, Yang, Hunger, Pieters, Schrappe, Biondi (bib2) 2015 Metelitsa (bib26) 2011 Tian, Zajac, Cell (bib14) 2016 Metelitsa, Naidenko, Kant, Wu, Loza, Perussia (bib25) 2001 Maury, Chevret, Thomas, Heim, Leguay, Huguet (bib4) 2016 Coquet (10.1016/j.yexcr.2018.11.008_bib15) 2013; 2 Kawano (10.1016/j.yexcr.2018.11.008_bib21) 1998 Kantarjian (10.1016/j.yexcr.2018.11.008_bib3) 2004 Wingender (10.1016/j.yexcr.2018.11.008_bib24) 2010 Gowda (10.1016/j.yexcr.2018.11.008_bib18) 2008; 111 Metelitsa (10.1016/j.yexcr.2018.11.008_bib25) 2001 Carreño (10.1016/j.yexcr.2018.11.008_bib33) 2016 Pilones (10.1016/j.yexcr.2018.11.008_bib8) 2012 Altman (10.1016/j.yexcr.2018.11.008_bib9) 2015 Dudek (10.1016/j.yexcr.2018.11.008_bib20) 2013 Coquet (10.1016/j.yexcr.2018.11.008_bib23) 2007 Metelitsa (10.1016/j.yexcr.2018.11.008_bib26) 2011 Bhatt (10.1016/j.yexcr.2018.11.008_bib17) 2015; 126 Nair (10.1016/j.yexcr.2018.11.008_bib7) 2017 Rossjohn (10.1016/j.yexcr.2018.11.008_bib6) 2012 Terabe (10.1016/j.yexcr.2018.11.008_bib11) 2003 Bai (10.1016/j.yexcr.2018.11.008_bib13) 2012 Fallarini (10.1016/j.yexcr.2018.11.008_bib29) 2012 Coquet (10.1016/j.yexcr.2018.11.008_bib12) 2008 Ngai (10.1016/j.yexcr.2018.11.008_bib16) 2018 Miura (10.1016/j.yexcr.2018.11.008_bib30) 2010 Brennan (10.1016/j.yexcr.2018.11.008_bib5) 2013 Terabe (10.1016/j.yexcr.2018.11.008_bib10) 2000 Kawano (10.1016/j.yexcr.2018.11.008_bib22) 1999 Maury (10.1016/j.yexcr.2018.11.008_bib4) 2016 De Santo (10.1016/j.yexcr.2018.11.008_bib32) 2010 Tian (10.1016/j.yexcr.2018.11.008_bib14) 2016 Nakagawa (10.1016/j.yexcr.2018.11.008_bib19) 2000 Spanoudakis (10.1016/j.yexcr.2018.11.008_bib27) 2009 Pui (10.1016/j.yexcr.2018.11.008_bib2) 2015 Hix (10.1016/j.yexcr.2018.11.008_bib28) 2011 Jabbour (10.1016/j.yexcr.2018.11.008_bib1) 2018 Song (10.1016/j.yexcr.2018.11.008_bib31) 2009 |
References_xml | – year: 1999 ident: bib22 article-title: Antitumor cytotoxicity mediated by ligand-activated human Vα24 NKT cells publication-title: Cancer Res. – year: 2004 ident: bib3 article-title: Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia publication-title: Cancer – year: 2012 ident: bib8 article-title: Invariant NKT cells as novel targets for immunotherapy in solid tumors publication-title: Clin. Dev. Immunol. – year: 2009 ident: bib31 article-title: Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages publication-title: J. Clin. Investig. – year: 2001 ident: bib25 article-title: Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells publication-title: J. Immunol. – year: 2003 ident: bib11 article-title: Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte–mediated tumor immunosurveillance publication-title: J. Exp. Med. – volume: 126 start-page: 1555 year: 2015 end-page: 1564 ident: bib17 article-title: Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma publication-title: Blood. Am. Soc. Hematol. – year: 2009 ident: bib27 article-title: Regulation of multiple myeloma survival and progression by CD1d publication-title: Blood – year: 2015 ident: bib2 article-title: Childhood Acute lymphoblastic leukemia: progress through collaboration publication-title: J. Clin. Oncol. – year: 2013 ident: bib5 article-title: Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions publication-title: Nat. Rev. Immunol. – year: 2010 ident: bib24 article-title: Antigen-specific cytotoxicity by invariant NKT cells in vivo is CD95/CD178-dependent and is correlated with antigenic potency publication-title: J. Immunol. – year: 2015 ident: bib9 article-title: Antitumor responses of invariant natural killer T cells publication-title: J. Immunol. Res. – year: 1998 ident: bib21 article-title: Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated V 14 NKT cells publication-title: Proc. Natl. Acad. Sci. – start-page: 1 year: 2018 end-page: 8 ident: bib1 article-title: Progress and Innovations in the management of adult acute lymphoblastic leukemia publication-title: JAMA Oncol. – year: 2000 ident: bib19 article-title: Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with the melanoma B16 hepatic metastasis and immunohistological study of tumor infiltrating cells publication-title: Oncol. Res. – year: 2012 ident: bib29 article-title: Invariant NKT cells increase drug-induced osteosarcoma cell death publication-title: Br. J. Pharmacol. – year: 2018 ident: bib16 article-title: IL-21 selectively protects CD62L + NKT cells and enhances their effector functions for adoptive immunotherapy publication-title: J. Immunol. – year: 2013 ident: bib20 article-title: Immature, semi-mature, and fully mature dendritic cells: toward a DC-cancer cells interface that augments anticancer immunity publication-title: Front. Immunol. – year: 2007 ident: bib23 article-title: IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production publication-title: J. Immunol. – year: 2008 ident: bib12 article-title: Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population publication-title: Proc. Natl. Acad. Sci. – year: 2010 ident: bib30 article-title: CD1d, a sentinel molecule bridging innate and adaptive immunity, is downregulated by the human papillomavirus (HPV) E5 protein: a possible mechanism for immune evasion by HPV publication-title: J. Virol. – year: 2016 ident: bib4 article-title: Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia publication-title: N. Engl. J. Med. – year: 2010 ident: bib32 article-title: Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A publication-title: Nat. Immunol. – year: 2012 ident: bib13 article-title: The majority of CD1d-sulfatide-specific T cells in human blood use a semiinvariant Vδ1 TCR publication-title: Eur. J. Immunol. – year: 2000 ident: bib10 article-title: NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway publication-title: Nat. Immunol. – year: 2012 ident: bib6 article-title: Recognition of CD1d-restricted antigens by natural killer T cells publication-title: Nat. Rev. Immunol. – volume: 111 start-page: 4723 year: 2008 end-page: 4730 ident: bib18 article-title: IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. blood publication-title: Am. Soc. Hematol. – volume: 2 start-page: e6 year: 2013 ident: bib15 article-title: IL-21 modulates activation of NKT cells in patients with stage IV malignant melanoma publication-title: Clin. Transl. Immunol. Nat. Publ. Group – year: 2017 ident: bib7 article-title: Natural killer T cells in cancer immunotherapy publication-title: Front. Immunol. – year: 2011 ident: bib26 article-title: Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans publication-title: Clin. Immunol. – year: 2011 ident: bib28 article-title: CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis publication-title: PLoS One – year: 2016 ident: bib33 article-title: Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents publication-title: Clin. Transl. Immunol. – year: 2016 ident: bib14 article-title: Differentiation: consider the context publication-title: Trends Immunol. – year: 2009 ident: 10.1016/j.yexcr.2018.11.008_bib27 article-title: Regulation of multiple myeloma survival and progression by CD1d publication-title: Blood doi: 10.1182/blood-2008-06-161281 – year: 2010 ident: 10.1016/j.yexcr.2018.11.008_bib32 article-title: Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A publication-title: Nat. Immunol. doi: 10.1038/ni.1942 – year: 2000 ident: 10.1016/j.yexcr.2018.11.008_bib10 article-title: NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway publication-title: Nat. Immunol. doi: 10.1038/82771 – year: 2010 ident: 10.1016/j.yexcr.2018.11.008_bib24 article-title: Antigen-specific cytotoxicity by invariant NKT cells in vivo is CD95/CD178-dependent and is correlated with antigenic potency publication-title: J. Immunol. doi: 10.4049/jimmunol.1001018 – year: 2008 ident: 10.1016/j.yexcr.2018.11.008_bib12 article-title: Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population publication-title: Proc. Natl. Acad. Sci. doi: 10.1073/pnas.0801631105 – year: 2015 ident: 10.1016/j.yexcr.2018.11.008_bib2 article-title: Childhood Acute lymphoblastic leukemia: progress through collaboration publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2014.59.1636 – year: 2009 ident: 10.1016/j.yexcr.2018.11.008_bib31 article-title: Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages publication-title: J. Clin. Investig. doi: 10.1172/JCI37869 – year: 1999 ident: 10.1016/j.yexcr.2018.11.008_bib22 article-title: Antitumor cytotoxicity mediated by ligand-activated human Vα24 NKT cells publication-title: Cancer Res. – year: 2001 ident: 10.1016/j.yexcr.2018.11.008_bib25 article-title: Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells publication-title: J. Immunol. doi: 10.4049/jimmunol.167.6.3114 – volume: 111 start-page: 4723 year: 2008 ident: 10.1016/j.yexcr.2018.11.008_bib18 article-title: IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. blood publication-title: Am. Soc. Hematol. – year: 2013 ident: 10.1016/j.yexcr.2018.11.008_bib20 article-title: Immature, semi-mature, and fully mature dendritic cells: toward a DC-cancer cells interface that augments anticancer immunity publication-title: Front. Immunol. doi: 10.3389/fimmu.2013.00438 – year: 2011 ident: 10.1016/j.yexcr.2018.11.008_bib28 article-title: CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis publication-title: PLoS One doi: 10.1371/journal.pone.0020702 – volume: 2 start-page: e6 year: 2013 ident: 10.1016/j.yexcr.2018.11.008_bib15 article-title: IL-21 modulates activation of NKT cells in patients with stage IV malignant melanoma publication-title: Clin. Transl. Immunol. Nat. Publ. Group doi: 10.1038/cti.2013.7 – volume: 126 start-page: 1555 year: 2015 ident: 10.1016/j.yexcr.2018.11.008_bib17 article-title: Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma publication-title: Blood. Am. Soc. Hematol. – year: 2012 ident: 10.1016/j.yexcr.2018.11.008_bib8 article-title: Invariant NKT cells as novel targets for immunotherapy in solid tumors publication-title: Clin. Dev. Immunol. doi: 10.1155/2012/720803 – year: 2016 ident: 10.1016/j.yexcr.2018.11.008_bib14 article-title: Differentiation: consider the context publication-title: Trends Immunol. doi: 10.1016/j.it.2016.06.001 – year: 2010 ident: 10.1016/j.yexcr.2018.11.008_bib30 article-title: CD1d, a sentinel molecule bridging innate and adaptive immunity, is downregulated by the human papillomavirus (HPV) E5 protein: a possible mechanism for immune evasion by HPV publication-title: J. Virol. doi: 10.1128/JVI.01053-10 – year: 2012 ident: 10.1016/j.yexcr.2018.11.008_bib6 article-title: Recognition of CD1d-restricted antigens by natural killer T cells publication-title: Nat. Rev. Immunol. doi: 10.1038/nri3328 – year: 2007 ident: 10.1016/j.yexcr.2018.11.008_bib23 article-title: IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production publication-title: J. Immunol. doi: 10.4049/jimmunol.178.5.2827 – year: 2015 ident: 10.1016/j.yexcr.2018.11.008_bib9 article-title: Antitumor responses of invariant natural killer T cells publication-title: J. Immunol. Res. doi: 10.1155/2015/652875 – year: 2016 ident: 10.1016/j.yexcr.2018.11.008_bib33 article-title: Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents publication-title: Clin. Transl. Immunol. doi: 10.1038/cti.2016.14 – year: 2003 ident: 10.1016/j.yexcr.2018.11.008_bib11 article-title: Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte–mediated tumor immunosurveillance publication-title: J. Exp. Med. doi: 10.1084/jem.20022227 – start-page: 1 year: 2018 ident: 10.1016/j.yexcr.2018.11.008_bib1 article-title: Progress and Innovations in the management of adult acute lymphoblastic leukemia publication-title: JAMA Oncol. – year: 2016 ident: 10.1016/j.yexcr.2018.11.008_bib4 article-title: Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1605085 – year: 2017 ident: 10.1016/j.yexcr.2018.11.008_bib7 article-title: Natural killer T cells in cancer immunotherapy publication-title: Front. Immunol. doi: 10.3389/fimmu.2017.01178 – year: 2012 ident: 10.1016/j.yexcr.2018.11.008_bib29 article-title: Invariant NKT cells increase drug-induced osteosarcoma cell death publication-title: Br. J. Pharmacol. doi: 10.1111/j.1476-5381.2012.02108.x – year: 2012 ident: 10.1016/j.yexcr.2018.11.008_bib13 article-title: The majority of CD1d-sulfatide-specific T cells in human blood use a semiinvariant Vδ1 TCR publication-title: Eur. J. Immunol. doi: 10.1002/eji.201242531 – year: 2000 ident: 10.1016/j.yexcr.2018.11.008_bib19 article-title: Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with the melanoma B16 hepatic metastasis and immunohistological study of tumor infiltrating cells publication-title: Oncol. Res. – year: 2013 ident: 10.1016/j.yexcr.2018.11.008_bib5 article-title: Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions publication-title: Nat. Rev. Immunol. doi: 10.1038/nri3369 – year: 2011 ident: 10.1016/j.yexcr.2018.11.008_bib26 article-title: Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans publication-title: Clin. Immunol. doi: 10.1016/j.clim.2010.10.005 – year: 2018 ident: 10.1016/j.yexcr.2018.11.008_bib16 article-title: IL-21 selectively protects CD62L + NKT cells and enhances their effector functions for adoptive immunotherapy publication-title: J. Immunol. doi: 10.4049/jimmunol.1800429 – year: 1998 ident: 10.1016/j.yexcr.2018.11.008_bib21 article-title: Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated V 14 NKT cells publication-title: Proc. Natl. Acad. Sci. doi: 10.1073/pnas.95.10.5690 – year: 2004 ident: 10.1016/j.yexcr.2018.11.008_bib3 article-title: Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia publication-title: Cancer doi: 10.1002/cncr.20668 |
SSID | ssj0008816 |
Score | 2.2752123 |
Snippet | Type I natural killer T (NKT) cells are attractive candidates for cancer immunotherapy. In this study, we examined the characteristics of type I NKT cells in... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 69 |
SubjectTerms | Acute lymphoblastic leukemia Adult Aged B-Lymphocytes - immunology CD8-Positive T-Lymphocytes - immunology Female Humans IL-21 Interleukins - blood Lymphocyte Count Male Middle Aged Natural killer T cells Natural Killer T-Cells - immunology Precursor Cell Lymphoblastic Leukemia-Lymphoma - blood Precursor Cell Lymphoblastic Leukemia-Lymphoma - immunology Receptors, Antigen, T-Cell, alpha-beta - metabolism Receptors, Interleukin-21 - metabolism |
Title | Impairment of Vα24-Jα18+Vβ11+ natural killer T cells in adult acute lymphoblastic leukemia patients |
URI | https://dx.doi.org/10.1016/j.yexcr.2018.11.008 https://www.ncbi.nlm.nih.gov/pubmed/30439366 https://www.proquest.com/docview/2135134446 |
Volume | 374 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwELYQFRKXqqWFbh_IlXqjgfUjjnNEqGihghMgblb8kgJLFrG7EnvhP9Efsr-pM04CqtRy6DGRHUffjMcz1sw3hHwLZRDcQaQatHSZLEOZWetVxiyEzwW3FS-xdvjkVI3O5fFlfrlCDvpaGEyr7Gx_a9OTte7e7HVo7t3WNdb4QjCgORhXgclWyPgpZYFavvvwnOahdWp_ioMzHN0zD6Ucr0W4d0gKyvQuUnlij8m_n07_8j7TKXT4hrzu3Ee63_7hW7ISmg2y1jaUXLwj8Qh2d32HN350EunF8pHL7Hj5yPTOxfIXYzs0EXnCF65TDSA9o3hzP6V1QxMTB63cfBboeAFCnljwrGEdOg7z63BTV7QjYZ2-J-eHP84ORlnXSSFzEHXOsiC5z12MApyf6PNQqspXxdAVLuQyai-0tDIq5h0fxqosPbdBWStAYJxrH8QmWW0mTfhAaMEcGzqQZ144WQisg7Vegx4wWXhZxQHhPYLGdTTj2O1ibPp8siuTYDcIOwQgBmAfkO9Pk25blo2Xh6teNOYPZTFwDrw88WsvSAPbCBGumjCZTw3HToUAj1QDstVK-OlPBJYPC6U-_u-yn8g6PJXtzc1nsjq7m4cv4MvM7HZS1m3yav_o5-j0N4f69dE |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LbxMxELZKKgQXxJsABSNxK0vjx3q9x6pqlfSRU1r1Zq1f0rZhUzWJRH5W-SH5TczsIxIS7aHXXb_0jT2esWa-IeR7yIPgDjzVoKVLZB7yxFqvEmbBfc64LXiOucNnYzU8l8eX6eUWOehyYTCsstX9jU6vtXX7Za9Fc--mLDHHF5wBzUG5Cgy2Ek_INrJTpT2yvT86GY43ClnrugIqtk-wQ0c-VId5rcJvh7ygTP9ENk8sM_n_C-o-A7S-iI5ekhetBUn3m0W-Iluhek2eNjUlV29IHMEBL2_x0Y_OIr1Y33GZHK_vmN69WP9hbJfWXJ4wwnWdBkgnFB_v57SsaE3GQQu3XAQ6XYGcZxaMa5iHTsPyOvwqC9rysM7fkvOjw8nBMGmLKSQOHM9FEiT3qYtRgP0TfRpyVfgiG7jMhVRG7YWWVkbFvOODWOS55zYoawXIjHPtg3hHetWsCh8IzZhjAwciTTMnM4GpsNZr2ApMZl4WsU94h6BxLdM4FryYmi6k7MrUsBuEHXwQA7D3yY9Np5uGaOPh5qoTjflnvxi4Ch7u-K0TpIGThAgXVZgt54ZjsUKAR6o-ed9IeLMSgRnEQqmPj532K3k2nJydmtPR-OQTeQ5_8uYh5zPpLW6XYQdMm4X90m7dv-80-II |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impairment+of+V%CE%B124-J%CE%B118+%2B+V%CE%B211+%2B+natural+killer+T+cells+in+adult+acute+lymphoblastic+leukemia+patients&rft.jtitle=Experimental+cell+research&rft.au=Zhao%2C+Haijun&rft.au=Li%2C+Zhifeng&rft.au=Xie%2C+Shiting&rft.au=Luo%2C+Yiming&rft.date=2019-01-01&rft.eissn=1090-2422&rft.volume=374&rft.issue=1&rft.spage=69&rft_id=info:doi/10.1016%2Fj.yexcr.2018.11.008&rft_id=info%3Apmid%2F30439366&rft.externalDocID=30439366 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0014-4827&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0014-4827&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0014-4827&client=summon |